

Molecular Pathways

- Transforming Growth Factor- β and the Immune Response to Malignant Disease.**
Beverly A. Teicher6247
- Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy.**
Elizabeth Ruth Plummer and Hilary Calvert6252

Human Cancer Biology

- Amplicon Mapping and Expression Profiling Identify the Fas-Associated Death Domain Gene as a New Driver in the 11q13.3 Amplicon in Laryngeal/Pharyngeal Cancer.**
Johan H. Gibcus, Lorian Menkema, Mirjam F. Mastik, Mario A. Hermsen, Geertruida H. de Bock, Marie-Louise F. van Velthuysen, Robert P. Takes, Klaas Kok, Cesar A. Álvarez Marcos, Bernard F.A.M. van der Laan, Michiel W.M. van den Brekel, Johannes A. Langendijk, Philip M. Kluin, Jacqueline E. van der Wal, and Ed Schuurung6257
- Identification of a Novel Cancer-Testis Antigen CRT2 Frequently Expressed in Various Cancers Using Representational Differential Analysis.** Emiko Hayashi, Yuriko Matsuzaki, Go Hasegawa, Tomonori Yaguchi, Sachiko Kurihara, Tomonobu Fujita, Toshiro Kageshita, Makoto Sano, and Yutaka Kawakami6267
- Identification and Validation of a Novel Gene Signature Associated with the Recurrence of Human Hepatocellular Carcinoma.** Suk Mei Wang, London Lucien P.J. Ooi, and Kam M. Hui6275
- Gene Expression Profiling from Formalin-Fixed Paraffin-Embedded Tumors of Pediatric Glioblastoma.** Takrima Haque, Damien Faury, Steffen Albrecht, Enrique Lopez-Aguilar, Péter Hauser, Miklós Garami, Zoltán Hanzély, László Bognár, Rolando F. Del Maestro, Jeffrey Atkinson, Andre Nantel, and Nada Jabado6284
- Hypermethylation of Tachykinin-1 Is a Potential Biomarker in Human Esophageal Cancer.**
Zhe Jin, Alexandru Olaru, Jian Yang, Fumiaki Sato, Yulan Cheng, Takatsugu Kan, Yuriko Mori, Carmit Mantzur, Bogdan Paun, James P. Hamilton, Tetsuo Ito, Suna Wang, Stefan David, Rachana Agarwal, David G. Beer, John M. Abraham, and Stephen J. Meltzer6293
- The Frequency and Suppressor Function of CD4⁺CD25^{high}Foxp3⁺ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck.** Laura Strauss, Christoph Bergmann, William Gooding, Jonas T. Johnson, and Theresa L. Whiteside6301
- Expression of Prenylated Rab Acceptor 1 Domain Family, Member 2 (PRAF2) in Neuroblastoma: Correlation with Clinical Features, Cellular Localization, and Cerulenin-Mediated Apoptosis Regulation.** Dirk Geerts, Christopher J. Wallick, Dana-Lynn T. Koomoa, Jan Koster, Rogier Versteeg, Ramon Christopher V. Go, and André S. Bachmann6312

Imaging, Diagnosis, Prognosis

- MCP-1 Promoter Polymorphism at -2518 Is Associated with Metastasis of Nasopharyngeal Carcinoma after Treatment.** Ka-Po Tse, Nang-Ming Tsang, Kung-Den Chen, Hsin-Pai Li, Ying Liang, Chuen Hsueh, Kai-Ping Chang, Jau-Song Yu, Sheng-Po Hao, Ling-Ling Hsieh, and Yu-Sun Chang6320
- The Prognostic Biomarkers HOXB13, IL17BR, and CHDH Are Regulated by Estrogen in Breast Cancer.** Zuncai Wang, Sonika Dahiya, Heather Provencher, Beth Muir, Erin Carney, Kathryn Coser, Toshi Shioda, Xiao-Jun Ma, and Dennis C. Sgroi6327
- A Self-Quenched Galactosamine-Serum Albumin-RhodamineX Conjugate: A "Smart" Fluorescent Molecular Imaging Probe Synthesized with Clinically Applicable Material for Detecting Peritoneal Ovarian Cancer Metastases.** Yukihiko Hama, Yasuteru Urano, Yoshinori Koyama, Andrew J. Gunn, Peter L. Choyke, and Hisataka Kobayashi6335

- Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response.** Selma Ugurel, Roland Houben, David Schrama, Heike Voigt, Marc Zapatka, Dirk Schadendorf, Eva B. Bröcker, and Jürgen C. Becker6344
- Prognostic Value of *LISCH7* mRNA in Plasma and Tumor of Colon Cancer Patients.** José M. García, Cristina Peña, Vanesa García, Gemma Domínguez, Concepción Muñoz, Javier Silva, Isabel Millán, Raquel Diaz, Yolanda Lorenzo, Rufo Rodriguez, and Félix Bonilla.....6351
- Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway.** Laurence Gamelin, Olivier Capitain, Alain Morel, Agnes Dumont, Sory Traore, Le Bouil Anne, Simard Gilles, Michele Boisdron-Celle, and Erick Gamelin.....6359
- Fluorine-18- α -Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study.** Kyoichi Kaira, Noboru Oriuchi, Yoshimi Otani, Kimihiro Shimizu, Shigebumi Tanaka, Hisao Imai, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Tamotsu Ishizuka, Kunio Dobashi, Yoshikatsu Kanai, Hitoshi Endou, Takashi Nakajima, Keigo Endo, and Masatomo Mori.....6369

Cancer Therapy: Clinical

- Daily Physical-Rest Activities in Relation to Nutritional State, Metabolism, and Quality of Life in Cancer Patients with Progressive Cachexia.** Marita Fouladiun, Ulla Körner, Lena Gunnebo, Petra Sixt-Ammilon, Ingvar Bosaeus, and Kent Lundholm6379
- Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting.** Craig L. Slingluff, Jr., Gina R. Petroni, Kimberly A. Chianese-Bullock, Mark E. Smolkin, Sarah Hibbitts, Cheryl Murphy, Naomi Johansen, William W. Grosh, Galina V. Yamshchikov, Patrice Y. Neese, James W. Patterson, Robyn Fink, and Patrice K. Rehm6386
- A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis.** Andrew J. Armstrong, Elizabeth S. Garrett-Mayer, Yi-Chun Ou Yang, Ronald de Wit, Ian F. Tannock, and Mario Eisenberger6396
- Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification.** Laurent Arnould, Patrick Arveux, Jerome Couturier, Marion Gelly-Marty, Catherine Loustalot, Francette Ettore, Christine Sagan, Martine Antoine, Frederique Penault-Llorca, Berangere Vasseur, Pierre Fumoleau, and Bruno P. Coudert6404
- Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group.** Markus Joerger, Alwin D.R. Huitema, Dick J. Richel, Christian Dittrich, Nikolas Pavlidis, Evangelos Briasoulis, Jan B. Vermorken, Elena Stocchi, Andrea Martoni, Roberto Sorio, Henk P. Sleetboom, Miguel A. Izquierdo, Duncan I. Jodrell, Hilary Calvert, Alan V. Boddy, Harry Hollema, Regine Féty, Wjf J.F. Van der Vijgh, Georg Hempel, Etienne Chatelut, Mats Karlsson, Justin Wilkins, Brigitte Tranchand, Ad H.G.J. Schrijvers, Christian Twelves, Jos H. Beijnen, and Jan H.M. Schellens6410

Cancer Therapy: Preclinical

- The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor-Positive Tumor Cells is Enhanced By Cytokines.** Julie M. Roda, Trupti Joshi, Jonathan P. Butchar, Jaclyn W. McAlees, Amy Lehman, Susheela Tridandapani, and William E. Carson III.....6419
- An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer.** Stephen R. Plymate, Kathy Haugk, Ilsa Coleman, Lillie Woodke, Robert Vessella, Peter Nelson, R. Bruce Montgomery, Dale L. Ludwig, and Jennifer D. Wu.....6429
- P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan.** Nienke A. de Vries, Jin Zhao, Emily Kroon, Tessa Buckle, Jos H. Beijnen, and Olaf van Tellingen6440

Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model. Teresa Troiani, Natalie J. Serkova, Daniel L. Gustafson, Thomas K. Henthorn, Owen Lockerbie, Andrea Merz, Michael Long, Mark Morrow, Fortunato Ciardiello, and S. Gail Eckhardt.....	6450
Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1α Autocrine Loop, and Reduces Orthotopic Tumor Growth. Sven A. Lang, Christian Moser, Andreas Gaumann, Dagmar Klein, Gabriel Glockzin, Felix C. Popp, Marc H. Dahlke, Pompiliu Piso, Hans J. Schlitt, Edward K. Geissler, and Oliver Stoeltzing.....	6459
Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma. Peter M. Voorhees, Qing Chen, Deborah J. Kuhn, George W. Small, Sally A. Hunsucker, John S. Strader, Robert E. Corringham, Mohamed H. Zaki, Jeffrey A. Nemeth, and Robert Z. Orlowski	6469
Nerve-Sparing Therapy with Oncolytic Herpes Virus for Cancers with Neural Invasion. Ziv Gil, Avigail Rein, Peter Brader, Sen Li, Jatin P. Shah, Yuman Fong, and Richard J. Wong	6479
A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer. Brad J. Stish, Hua Chen, Yanqun Shu, Angela Panoskaltis-Mortari, and Daniel A. Vallera.....	6486
Defucosylated Anti-CC Chemokine Receptor 4 Monoclonal Antibody Combined with Immunomodulatory Cytokines: A Novel Immunotherapy for Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome. Hiroki Yano, Takashi Ishida, Atsushi Inagaki, Toshihiko Ishii, Jianmin Ding, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki, and Ryuzo Ueda.....	6494
Immunization with Mimotopes Prevents Growth of Carcinoembryonic Antigen-Positive Tumors in BALB/c Mice. Kira H. Brämswig, Regina Knittelfelder, Silke Gruber, Eva Untermayr, Angelika B. Riemer, Krisztina Szalai, Reinhard Horvat, Robert Kammerer, Wolfgang Zimmermann, Christoph C. Zielinski, Otto Scheiner, and Erika Jensen-Jarolim	6501
Apicularen A Induces Cell Death through Fas Ligand Up-Regulation and Microtubule Disruption by Tubulin Down-Regulation in HM7 Human Colon Cancer Cells. Jong-Seok Kim, Young-Chul Lee, Ho-Tak Nam, Ge Li, Eun-Jin Yun, Kyoung-Sub Song, Kang-Sik Seo, Ji-Hoon Park, Jong-Woong Ahn, OkPyo Zee, Jong-Il Park, Wan-Hee Yoon, Kyu Lim, and Byung-Doo Hwang	6509
Buccal Mucosa Cells as <i>In vivo</i> Model to Evaluate Gefitinib Activity in Patients with Advanced Non-Small Cell Lung Cancer. Maura Loprevite, Marcello Tiseo, Maurizio Chiamondia, Marzia Capelletti, Cecilia Bozzetti, Beatrice Bortesi, Nadia Naldi, Rita Nizzoli, Patrizia Dadati, Annalisa Kunkl, Daniela Zennaro, Costanza Lagrasta, Nicoletta Campanini, Elena Spiritelli, Roberta Camisa, Francesco Grossi, Guido Rindi, Vittorio Franciosi, and Andrea Ardizzoni.....	6518

Cancer Susceptibility and Prevention

5-Aminosalicylic Acid Given in the Remission Stage of Colitis Suppresses Colitis-Associated Cancer in a Mouse Colitis Model. Ikuko Ikeda, Ayako Tomimoto, Koichiro Wada, Toshio Fujisawa, Koji Fujita, Kyoko Yonemitsu, Yuichi Nozaki, Hiroki Endo, Hirokazu Takahashi, Masato Yoneda, Masahiko Inamori, Kensuke Kubota, Satoru Saito, Yoji Nagashima, Hitoshi Nakagama, and Atsushi Nakajima	6527
Repair Capacity for UV Light-Induced DNA Damage Associated with Risk of Nonmelanoma Skin Cancer and Tumor Progression. Li-E Wang, Chunying Li, Sara S. Strom, Leonard H. Goldberg, Abenaa Brewster, Zhaozheng Guo, Yawei Qiao, Gary L. Clayman, J. Jack Lee, Adel K. El-Naggar, Victor G. Prieto, Madeleine Duvic, Scott M. Lippman, Randal S. Weber, Margaret L. Kripke, and Qingyi Wei	6532

Letters to the Editor

Clarification Regarding “Phase II Trials Published in 2002: A Cross-Specialty Comparison Showing Significant Design Differences between Oncology Trials and Other Medical Specialties” and the Accompanying Commentary, “Phase II Cancer Trials: Out of Control?”

Bruce A. Chabner and Mark J. Ratain.....6540

Bortezomib Sensitizes Human Astrocytoma Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis. Athanassios P. Kyritsis, Fanny Tachmazoglou,

Jasti S. Rao, and Vinay K. Puduvalli6540

Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL. Ronald Koschny,

Jaromir Sykora, Henning Walczak, Tom M. Ganten, Tobias L. Haas, Martin R. Sprick, Heidrum Holland, Peter Ahnert, Wolfgang Krupp, Jürgen Meixensberger, and Manfred Bauer6541


Corrections

Correction: Article on Bortezomib Inhibition of Nuclear Factor-KB-Dependent Survival6543

Correction: Article on the Tumor Suppression Activities of CMTM56543

About the Cover

Immunocytochemical staining of p-MAPK (50% ++) at baseline on buccal mucosa cells in patient responder to gefitinib treatment (combination of percentage of positive cells and staining intensity [negative 0, weak 1+, moderate 2+ and strong 3+]) (×200 original magnification). For further details, please see the article by Loprevite and associates on page 6518 of this issue.



Clinical Cancer Research

13 (21)

Clin Cancer Res 2007;13:6247-6543.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/13/21>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/13/21>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.